VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Thursday, March 20th.

VolitionRx Stock Performance

VolitionRx stock opened at $0.53 on Friday. The stock has a market capitalization of $48.93 million, a P/E ratio of -1.47 and a beta of 1.09. The company’s fifty day moving average price is $0.59 and its 200 day moving average price is $0.64. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.02.

Insider Buying and Selling

In other VolitionRx news, CEO Cameron John Reynolds bought 181,818 shares of the company’s stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average price of $0.55 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief executive officer now directly owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. This represents a 8.59 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently bought and sold shares of VNRX. Two Sigma Securities LLC acquired a new stake in VolitionRx in the 4th quarter valued at about $29,000. Millennium Management LLC acquired a new position in shares of VolitionRx during the 4th quarter worth approximately $36,000. Northern Trust Corp grew its position in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. lifted its position in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.